A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)
Phase of Trial: Phase IV
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms DOL-ART
- Sponsors ViiV Healthcare
- 27 Oct 2017 Results of 2nd interim analysis (data cut 27 months after last patient in) assessing safety and efficacy presented at the 16th European AIDS Conference
- 23 Oct 2017 Status changed from active, no longer recruiting to completed.
- 16 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 May 2017.